Daily Watch List For March 19th 2012 : Recon Technology, Ampio Pharmaceuticals & AISystems Inc

Share Article

Stock Daily Watch List : Recon Technology, Reading International, Ampio Pharmaceuticals & AISystems Inc American Penny Stocks Research Report Pioneer is offering its VIP membership for free to investors and traders looking to successfully navigate the Micro Cap and Small Cap Markets. issues weekly alerts to members looking for momentum, low float and bounce plays as well as Trading Tips.

Recon Technology, Ltd. is a non-state-owned oil field service company in China. The company has been providing software, equipments and services designed to increase the efficiency and automation in oil and gas exploration, extraction, production and refinery for Chinese oil and gas fields for more than 10 years.

Recon Technology is up more than 200% today upon positive news. Recon Technology announced today that one of its variable interest entities, Beijing BHD Petroleum Technology Co., Ltd. ("BHD"), introduced the Baker Hughes Frac-PointTM System to China Petroleum and Chemical Corporation's ("Sinopec") Zhongyuan oilfield.

The system helped Sinopec complete the fracturing of a dense sandstone horizontal well that required multistate fracturing. This cooperation positions BHD very well in meeting Sinopec's further fracturing needs. As of March 19, 2012, BHD has signed several contracts with an accumulated contract value of RMB 30 million (approximately $4.75 million). These contracts will be performed in different stages and are expected to be completed during the first half of 2012.

Click to Get the Full Stock Report on Recon Technology.

Ampio Pharmaceuticals, a biopharmaceutical company conducting clinical trials on its three lead drugs (Zertane™ completed two phase III studies, Ampion™-completed proof of concept studies and Optina™), licensing distribution of these drugs and engaged in further drug development, today announced that it completed the planned interim review of the first 50% of patients enrolled in the Optina™ trial for diabetic macular edema.

Based on these positive and encouraging results and the potential of lack of efficacy at the higher doses, both doses being present in this study, Ampio decided to conclude this study ahead of schedule and to proceed with the preparation of a consultation package for the FDA that includes the basic science and clinical results for discussion of the design of a pivotal trial in the US under the 505(b)2 regulation for repurposed drugs.

Ampio Pharmaceuticals had traded as high as $4.58 today almost $2.00 above previous closing price of $2.68.

Click to Get the Full Stock Report on Ampio Pharmaceuticals

Today’s Penny Stock Pick is AISystems. Volume has exploded today and shares have been trading as much as 5 times the previous close price.

Click to get the Full Stock Report on AISystems Inc.

Stock Reports provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the newsletter and receiving alerts from a Pro-Active team of researchers.

Stock Reports believes traders should have a chance at successfully trading Penny Stocks and invites traders and investors you to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here:

Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. is a wholly owned entity of a financial public relations firm. We have not been compensated by any of these companies for this release. Please read our report and visit our website, for complete risks and disclosures.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website